Cost-effectiveness of watchful waiting versus immediate emergency department transfer after epinephrine autoinjector use in Canada

Yin, Y., Shoshan, M.B., Shaker, M. et al. Allergy Asthma Clin Immunol 21, 5 (2025). https://doi.org/10.1186/s13223-025-00951-w

Abstract

Background

Until recently, immediate emergency department (ED) transfer after food-related anaphylactic reactions was recommended regardless of symptom resolution following use of an epinephrine autoinjector (EAI). We evaluated the cost-effectiveness of delayed ED transfer after EAI use in non-medical settings (watchful waiting) compared to immediate ED transfer among pediatric patients with food allergies in Canada.

Methods

We developed a probabilistic Markov model of individuals starting at age of one year who are at risk of severe food-related allergic reactions requiring epinephrine. We evaluated medical costs (in 2022 Canadian dollars) and quality-adjusted life years (QALY) of each strategy over a 20-year horizon. In the base case, we assumed a tenfold increase in food allergy fatality for patients under watchful waiting, which we increased to 100- to 1,000-fold in sensitivity analysis.

Natural history of sesame allergy in pediatric patients: Insight from a retrospective analysis.

Kazancioglu A, Ocak M, Sahiner UM, Soyer O, Sekerel BE.  Pediatr Allergy Immunol. 2025; 36:e70022. doi:10.1111/pai.70022

Abstract

Background

Sesame allergy (SA) is a growing concern because of its association with severe reactions and the limited knowledge of long-term outcomes.

Objective

This retrospective study aimed to identify the risk factors influencing persistent SA (PSA) in children to improve management and select suitable candidates for oral immunotherapy (OIT).

Methods

We analyzed the electronic medical records of 84 children with confirmed SA, as defined by consistent clinical reactions and immunoglobulin E (IgE)-mediated sensitization. Patients were followed for a median (IQR) of 56.5 (46.0–82.5) months.

Efficacy and safety of intranasal medications for allergic rhinitis: Network meta-analysis

Sousa-Pinto B, Vieira RJ, Bognanni A, et al.  Allergy. 2025; 80: 94-105. doi:10.1111/all.16384

Abstract

Background

Intranasal antihistamines (INAH), corticosteroids (INCS), and their fixed combinations (INAH+INCS) are one of the cornerstones of the treatment of allergic rhinitis (AR). We performed a systematic review and network-meta-analysis comparing the efficacy and safety of INAH, INCS, and INAH+INCS in patients with AR.

Methods

We searched four electronic bibliographic databases and three clinical trial databases for randomised controlled trials assessing the use of INAH, INCS, and INAH+INCS in adults with seasonal or perennial AR. We performed a network meta-analysis on the Total Nasal Symptom Score, Total Ocular Symptom Score, Rhinoconjunctivitis Quality-of-Life Questionnaire, development of adverse events, and withdrawals due to adverse events.

Determination of the Bioavailability of 3 Intranasal Formulations of Azelastine Hydrochloride in Healthy Male Volunteers

Bousquet, J., Klimek, L., Liu, M., Nguyen, D.T., Ramalingam, R.K., Canonica, G.W. and Berger, W.E. (2025), Clin Pharmacol Drug Dev. https://doi.org/10.1002/cpdd.1498

Abstract

The primary objective of the study was to determine the bioavailability of 2 new formulations of azelastine (AZE) hydrochloride (0.10% and 0.15% AZE) containing sorbitol and sucralose compared with the commercially available 0.10% AZE. This study was performed in healthy volunteers based on the pharmacokinetic parameters maximum plasma concentration and area under the plasma concentration–time curve from time zero to the last measurable concentration. This was a Phase 1, open-label, single-center, randomized, parallel-group study.

Mean azelastine plasma concentration with time.

Subjects were randomized to 1 of 3 treatment groups: (1) 0.10% AZE (treatment A), (2) 0.15% AZE (treatment B) (Groups 1 and 2 both containing sorbitol and sucralose), and (3) the commercially available 0.10% AZE (treatment C). A total of 54 subjects were randomized and received treatment A, B, or C.

The present and future of digital health, digital medicine, and digital therapeutics for allergic diseases

Zhang H, Cao Y, Jiang H, Zhou Q, Yang Q, Cheng L. Clin Transl Allergy. 2025;e70020. https://doi.org/10.1002/clt2.70020

Abstract

Background

Digital health, digital medicine, and digital therapeutics integrate advanced computer technologies into healthcare, aiming to improve efficiency and patient outcomes. These technologies offer innovative solutions for the management of allergic diseases, which affect a significant proportion of the global population and are increasing in prevalence.

Application scenarios of digital health in allergy for both physicians and patients.

Body

This review examines the current progress and future potential of digital health in allergic disease management. It highlights key advancements, including telehealth, mobile health (mHealth), artificial intelligence, clinical decision support systems (CDSS), and digital biomarkers, with a focus on their relevance to allergic disease management.

Immunoglobulin replacement therapy in patients with primary and secondary immunodeficiencies: impact of infusion method on immunoglobulin-specific perceptions of quality of life and treatment satisfaction

Mallick, R., Hahn, N. & Scalchunes, C. Allergy Asthma Clin Immunol 21, 2 (2025). https://doi.org/10.1186/s13223-024-00939-y

Abstract

Background

Immunoglobulin replacement therapy (IgRT) is the current standard of care for primary antibody deficiency patients (majority of all primary immunodeficiency (PID) diseases), with growing real-world evidence supporting use for secondary immunodeficiency (SID) patients. Infusion methods and practices can affect patients’ satisfaction with their treatment and perception of their health-related quality of life.

Methods

An online survey of US patients with PID and SID was conducted. This research investigates primarily the impact of two IgRT infusion methods, intravenous immunoglobulin therapy (IVIG) and subcutaneous immunoglobulin (SCIG), on the patient reported outcome (PRO) Life Quality Index (LQI) tool.

Allergic Rhinitis: Impact on Quality of Life

Nuhi A, Jintu A, Amresh K, Harinderjit S. Ann Pulm Res Med. 2024; 2(1): 1007.

Abstract

Besides its usual symptoms, allergic rhinitis has a substantial negative influence on one's physical and emotional well-being as well as social and mental interactions and overall Quality of Life (QOL). Environmental causes and changes in lifestyle are contributing to its rising global incidence. Nasal congestion symptoms can make it difficult to sleep, wear you out, and interfere with everyday activities, especially when they coexist with other disorders like asthma. Studies have demonstrated the efficacy of medication and variations in prevalence according to gender. This research attempts to assess the effects of allergic rhinitis on quality of life in detail. Pharmacotherapy and avoiding allergens are the best forms of treatment. When appropriate, targeted symptom control with immunotherapy and an assessment for allergic rhinitis should be taken into account.

Cost-of-illness analysis of chronic urticaria clinical management in five countries of Latin America

Sánchez J, Álvarez L, Larco JI, et al. Clin Transl Allergy. 2025;e70016. https://doi.org/10.1002/clt2.70016

Abstract

Introduction

Chronic spontaneous urticaria (CSU) is a disease with a high impact on the quality of life of patients. There are some evaluations of the economic cost of the disease in developed countries, but there is little information about the economic cost of the disease in developing countries. Our aim was to assess the economic diagnostic and therapeutic expenses of CSU in five Latin American (LA) countries.

Methods

A noninterventional multicenter cross-sectional study was conducted in five LA countries: Brazil, Colombia, Ecuador, Mexico, and Peru.